Loratadine Market (By Grade Type: USP Standard Grade, EP Standard Grade, Medicine Standard Grade; By Dosage Form; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global loratadine market size was estimated at USD 153.44 million in 2023 and it is expected to surpass around USD 205.21 million by 2033, poised to grow at a CAGR of 2.95% from 2024 to 2033. The loratadine market encompasses a comprehensive landscape of pharmaceuticals, driven by factors ranging from consumer demand to regulatory dynamics and technological advancements. Loratadine, a widely used antihistamine medication, is renowned for its effectiveness in alleviating symptoms associated with allergies such as sneezing, itching, and runny nose.

Loratadine Market Size 2024 to 2033

Key Pointers

  • North America led the market share in 2023.
  • Asia Pacific is predicted to witness the fastest CAGR from 2024 to 2033.
  • By Grade Type, the USP standard grade segment held the largest market share in 2023.
  • By Dosage Form, the tablets segment dominated the market in 2023.
  • By End-use, the online pharmacy segment is expected to grow at the fastest CAGR during the forecast period.

Loratadine Market Growth

The growth of the loratadine market is propelled by several key factors. Firstly, the increasing prevalence of allergic disorders worldwide, such as allergic rhinitis and urticaria, contributes significantly to the rising demand for antihistamine medications like loratadine. Additionally, the trend towards self-medication and the availability of loratadine as an over-the-counter (OTC) medication further bolster market expansion. Pharmaceutical companies' continuous efforts to innovate and improve loratadine formulations, including advancements in delivery systems and combination therapies, also drive market growth. Moreover, expanding healthcare expenditure, coupled with rising awareness about allergy management, continues to fuel the demand for loratadine, positioning the market for sustained growth in the foreseeable future.

Loratadine Market Trends:

  • Increasing Prevalence of Allergic Disorders: The rising incidence of allergic conditions like allergic rhinitis and urticaria globally is driving the demand for loratadine and other antihistamine medications.
  • Growing Preference for Over-the-Counter (OTC) Medications: There is a notable shift towards self-medication, with consumers increasingly seeking convenient OTC options for managing common allergies, contributing to the market growth of loratadine.
  • Advancements in Formulations and Delivery Systems: Pharmaceutical companies are focusing on developing innovative loratadine formulations, including fast-dissolving tablets, liquid formulations, and combination therapies, to enhance efficacy and patient compliance.
  • Expanding Market Reach through Online Pharmacies: The proliferation of online pharmacies provides consumers with convenient access to loratadine and other medications, thereby expanding the market reach and accessibility of these products.
  • Increasing Adoption in Emerging Markets: Emerging economies are witnessing a growing awareness of allergy management and an increasing demand for effective antihistamine medications like loratadine, driving market growth in these regions.
  • Strategic Collaborations and Partnerships: Key players in the loratadine market are forming strategic collaborations and partnerships to strengthen their product portfolios, expand their market presence, and capitalize on emerging opportunities in the pharmaceutical industry.

Grade Type Insights

Based on the grade type, the market is segmented into USP Standard Grade, EP Standard Grade, Medicine Standard Grade, and others. The USP standard grade segment held the largest market share in 2023. USP standard grade emphasis on regulatory compliance with established quality and safety regulations, thereby accelerating customer preference and adoption rate.

Dosage Form Insights

On the basis of dosage form, the market is segmented into tablets, capsules, syrup, and others. The tablets segment dominated the market in 2023 due to patient convenience, ease of administration, high availability, reliability, and longer shelf life. The strong presence of several industry participants who are manufacturing loratadine tablets in various strengths to cater to a large population base will accelerate the segment growth over the forecast period.

End-use Insights

Based on end-use, the loratadine market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The online pharmacy segment is expected to grow at the fastest CAGR during the forecast period. Upsurge in the adoption of online platforms owing to large availability and accessibility to diverse product offerings, affordable pricing, and offers driving segmental demand. Moreover, the integration of online pharmacy platforms with telemedicine is expected to provide enormous growth opportunities to the segment.

Regional Insights

North America dominated the market share in 2023. The high disease burden and strong presence of several manufacturers are anticipated to propel market growth in this region. Increasing prevalence of seasonal and perennial allergies in the region, accelerating demand for antihistamine medications, including loratadine. The surge in population awareness regarding allergy and consumer preference towards non-drowsy formulations is estimated to spur regional revenue growth potential.

Loratadine Market Share, By Region, 2023 (%)

Asia Pacific is predicted to witness the fastest CAGR over the forecast period. Rapidly growing awareness regarding allergic ailments, the rising geriatric population that is highly prone to several allergic conditions, and the increasing prevalence of lifestyle diseases are factors driving the Asia Pacific loratadine market.

Loratadine Market Key Companies

  • Merck (U.S.)
  • Cadila Pharmaceuticals (India)
  • Morepen (India)
  • Ultratech India (India)
  • Vasudha Pharma Chem (India)
  • Hetero Drugs (India)
  • Mylan (U.S.)
  • Changzhou Yabang (China)
  • Shaanxi Hanjiang (China)
  • Inke, S.A. (Spain)
  • Argon Drugs (India)

Loratadine Market Segmentations:

By Grade Type

  • USP Standard Grade
  • EP Standard Grade
  • Medicine Standard Grade

By Dosage Form

  • Tablets
  • Capsules
  • Syrup
  • Others

By End-use

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global loratadine market size was reached at USD 153.44 million in 2023 and it is projected to hit around USD 205.21 million by 2033.

The global loratadine market is growing at a compound annual growth rate (CAGR) of 2.95% from 2024 to 2033.

The North America region has accounted for the largest loratadine market share in 2023.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Grade Type Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Loratadine Market 

5.1. COVID-19 Landscape: Loratadine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Loratadine Market, By Grade Type

8.1. Loratadine Market, by Grade Type, 2024-2033

8.1.1 USP Standard Grade

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. EP Standard Grade

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Medicine Standard Grade

8.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Loratadine Market, By Dosage Form

9.1. Loratadine Market, by Dosage Form, 2024-2033

9.1.1. Tablets

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Capsules

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Syrup

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Loratadine Market, By End-use 

10.1. Loratadine Market, by End-use, 2024-2033

10.1.1. Hospital Pharmacy

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Retail Pharmacy

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Online Pharmacy

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Loratadine Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.1.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.1.3. Market Revenue and Forecast, by End-use (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.1.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.1.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.2.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.2.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.2.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.2.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.2.6.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.2.7.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.3.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.3.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.3.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.3.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.3.6.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.3.7.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.4.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.4.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.4.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.4.6.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.4.7.3. Market Revenue and Forecast, by End-use (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.5.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.5.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Grade Type (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Dosage Form (2021-2033)

11.5.5.3. Market Revenue and Forecast, by End-use (2021-2033)

Chapter 12. Company Profiles

12.1. Merck (U.S.)

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Cadila Pharmaceuticals (India).

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Morepen (India).

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Ultratech India (India).

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Vasudha Pharma Chem (India).

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Hetero Drugs (India)

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Mylan (U.S.).

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Changzhou Yabang (China)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Shaanxi Hanjiang (China).

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Inke, S.A. (Spain)

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask to Expert